Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?

Figure 1 The overall survival rate tended to be superior in group A (a solid line) than in group B (a dotted line) (3-, 6-, 12-, 24-, and 36 mo = 82. 6%, 78.3%, 56.5%, 32.8% and 21.9% vs 94.7%, 73.7%, 42.1%, 18.4%, and 6.1%, respectively, P = 0.203).

Figure 2 The progression-free survival rate was significantly superior in group A (a solid line) than in group B (a dotted line) (3-, 6-, 12-, and 24 mo = 82. 6%, 69.6%, 29.3%, and 19.6% vs 63.2%, 42.1%, 15.8% and 0%, respectively, P = 0.040).

Figure 3 The overall survival rate and survival time tended to be superior in group A’ (a solid line) than in group B (a dotted line) (3-, 6-, 12-, 24-, and 36 mo = 75. 0%, 75.0%, 62.5%, 50.0% and 37.5% vs 94.7%, 73.7%, 42.1%, 18.4%, and 6.1%, respectively, P = 0.095).

Figure 4 The progression-free survival rate and time tended to be superior in group A’ (a solid line) than in group B (a dotted line) (3-, 6-, 12-, and 24 mo = 75. 0%, 75.0%, 25.0%, and 0% vs 63.2%, 42.1%, 15.8% and 0%, respectively, P = 0.192).